CompletedPhase 2NCT03389308
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Studying Epidermolysis bullosa simplex
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Castle Creek Pharmaceuticals, LLC
- Principal Investigator
- Mary Spellman, MDCastle Creek Pharmaceuticals
- Intervention
- diacerein 1% ointment(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 99 years · All sexes
- Timeline
- 2017 – 2020
Study locations (3)
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill, North Carolina, United States
- Children's Hospital of San Antonio, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03389308 on ClinicalTrials.govOther trials for Epidermolysis bullosa simplex
Additional recruiting or active studies for the same condition.